Presentations by Event

Presented at 2017 ACS Meeting, San Francisco, CA, April 2017

Discovery of ETX2514, a novel, rationally designed inhibitor of Class A, C and D β–lactamases, for the treatment of Gram-negative infections

Thomas Durand-Reville, ACS 2017

Program(s): durlobactam (etx2514)

Presented at SDRI, Brisbane, Australia, April 2017

Pathogen-directed strategies at Entasis Therapeutics

Alita Miller, SDRI 2017

Program(s): durlobactam (etx2514)

Presented at 2017 Gordon Research Conference: Multi-Drug Efflux Systems, Galveston, TX, March 2017

Antibiotic Resistance: A real and present danger in our hospitals

Ruben Tommasi, Gordon Research Conference 2017